Nation approves new tool in breast cancer treatment
The China Post news staffTAIPEI, Taiwan -- Health authorities in Taiwan have approved a new targeted therapy treating HER2-positive breast cancer, doctors reported.
October 5, 2013, 12:01 am TWN
Patients of some breast cancers test positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells, doctors said.
Since HER2-targeted therapy was introduced in 1998, more than 1.3 million patients of this kind of breast cancer have benefited from treatment worldwide.
But researchers have now developed a HER2/HER3-targeted therapy that has been clinically proven to be able to extend the life expectancy of breast cancer patients from 36 months to 45, if combined with HER2-targeted therapy, doctors said.
Chen Hsun-che, a surgeon from Taipei's Chang Gung Memorial Hospital, explained that the new therapy blocks HER2 and HER3 from forming dimers that will promote strong growth of cancer cells.